Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: Identification of prognostic microenvironmental factors after chemoradiation

Yoshitaka Zenke, Genichiro Ishii, Yuichiro Ohe, Kaoru Kaseda, Tatsuya Yoshida, Shingo Matsumoto, Shigeki Umemura, Kiyotaka Yoh, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Takeshi Kuwata, Kanji Nagai, Atsushi Ochiai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prognostic factors for patients with non-small cell lung cancer (NSCLC) who have been treated with neoadjuvant therapy have not been fully assessed. The purpose of this study was to analyze prognostic biomarkers in NSCLC after treatment with neoadjuvant therapy, with special reference to the immunophenotypes of both the cancer cells and stromal cells. A total of 52 patients with NSCLC who were treated with neoadjuvant therapy followed by complete resection were included. We examined the expressions of nine markers in the cancer cells and stromal cells. The 5-year disease-free survival rate of patients with high aldehyde dehydrogenase 1 (ALDH1) expression levels in their cancer cells was significantly lower than those with a low ALDH1 level (47.3% vs. 21.5%, respectively; P = 0.023). The other molecules expressed in cancer cells did not exhibit any prognostic value. In NSCLC without neoadjuvant therapy (case control, n = 104), expression of ALDH1 in cancer cells was not correlated with prognosis (P = 0.507). A multivariate analysis identified ALDH1 expression in cancer cells as significantly independent prognostic factors for disease-free survival (P = 0.045). The current study indicated that the immunophenotypes of ALDH1 in cancer cells could have prognostic value for patients with NSCLC who are treated with neoadjuvant therapy.

Original languageEnglish
Pages (from-to)599-606
Number of pages8
JournalPathology International
Volume63
Issue number12
DOIs
Publication statusPublished - 2013 Dec
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Non-Small Cell Lung Carcinoma
Neoplasms
Stromal Cells
Disease-Free Survival
aldehyde dehydrogenase 1
Multivariate Analysis
Survival Rate
Biomarkers

Keywords

  • ALDH1
  • Cancer stromal cell
  • Cancer-initiating cell
  • Neoadjuvant therapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy : Identification of prognostic microenvironmental factors after chemoradiation. / Zenke, Yoshitaka; Ishii, Genichiro; Ohe, Yuichiro; Kaseda, Kaoru; Yoshida, Tatsuya; Matsumoto, Shingo; Umemura, Shigeki; Yoh, Kiyotaka; Niho, Seiji; Goto, Koichi; Ohmatsu, Hironobu; Kuwata, Takeshi; Nagai, Kanji; Ochiai, Atsushi.

In: Pathology International, Vol. 63, No. 12, 12.2013, p. 599-606.

Research output: Contribution to journalArticle

Zenke, Yoshitaka ; Ishii, Genichiro ; Ohe, Yuichiro ; Kaseda, Kaoru ; Yoshida, Tatsuya ; Matsumoto, Shingo ; Umemura, Shigeki ; Yoh, Kiyotaka ; Niho, Seiji ; Goto, Koichi ; Ohmatsu, Hironobu ; Kuwata, Takeshi ; Nagai, Kanji ; Ochiai, Atsushi. / Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy : Identification of prognostic microenvironmental factors after chemoradiation. In: Pathology International. 2013 ; Vol. 63, No. 12. pp. 599-606.
@article{489fa56db843421fbba0c0bb5b62b1e4,
title = "Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: Identification of prognostic microenvironmental factors after chemoradiation",
abstract = "Prognostic factors for patients with non-small cell lung cancer (NSCLC) who have been treated with neoadjuvant therapy have not been fully assessed. The purpose of this study was to analyze prognostic biomarkers in NSCLC after treatment with neoadjuvant therapy, with special reference to the immunophenotypes of both the cancer cells and stromal cells. A total of 52 patients with NSCLC who were treated with neoadjuvant therapy followed by complete resection were included. We examined the expressions of nine markers in the cancer cells and stromal cells. The 5-year disease-free survival rate of patients with high aldehyde dehydrogenase 1 (ALDH1) expression levels in their cancer cells was significantly lower than those with a low ALDH1 level (47.3{\%} vs. 21.5{\%}, respectively; P = 0.023). The other molecules expressed in cancer cells did not exhibit any prognostic value. In NSCLC without neoadjuvant therapy (case control, n = 104), expression of ALDH1 in cancer cells was not correlated with prognosis (P = 0.507). A multivariate analysis identified ALDH1 expression in cancer cells as significantly independent prognostic factors for disease-free survival (P = 0.045). The current study indicated that the immunophenotypes of ALDH1 in cancer cells could have prognostic value for patients with NSCLC who are treated with neoadjuvant therapy.",
keywords = "ALDH1, Cancer stromal cell, Cancer-initiating cell, Neoadjuvant therapy, Non-small cell lung cancer",
author = "Yoshitaka Zenke and Genichiro Ishii and Yuichiro Ohe and Kaoru Kaseda and Tatsuya Yoshida and Shingo Matsumoto and Shigeki Umemura and Kiyotaka Yoh and Seiji Niho and Koichi Goto and Hironobu Ohmatsu and Takeshi Kuwata and Kanji Nagai and Atsushi Ochiai",
year = "2013",
month = "12",
doi = "10.1111/pin.12122",
language = "English",
volume = "63",
pages = "599--606",
journal = "Pathology International",
issn = "1320-5463",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy

T2 - Identification of prognostic microenvironmental factors after chemoradiation

AU - Zenke, Yoshitaka

AU - Ishii, Genichiro

AU - Ohe, Yuichiro

AU - Kaseda, Kaoru

AU - Yoshida, Tatsuya

AU - Matsumoto, Shingo

AU - Umemura, Shigeki

AU - Yoh, Kiyotaka

AU - Niho, Seiji

AU - Goto, Koichi

AU - Ohmatsu, Hironobu

AU - Kuwata, Takeshi

AU - Nagai, Kanji

AU - Ochiai, Atsushi

PY - 2013/12

Y1 - 2013/12

N2 - Prognostic factors for patients with non-small cell lung cancer (NSCLC) who have been treated with neoadjuvant therapy have not been fully assessed. The purpose of this study was to analyze prognostic biomarkers in NSCLC after treatment with neoadjuvant therapy, with special reference to the immunophenotypes of both the cancer cells and stromal cells. A total of 52 patients with NSCLC who were treated with neoadjuvant therapy followed by complete resection were included. We examined the expressions of nine markers in the cancer cells and stromal cells. The 5-year disease-free survival rate of patients with high aldehyde dehydrogenase 1 (ALDH1) expression levels in their cancer cells was significantly lower than those with a low ALDH1 level (47.3% vs. 21.5%, respectively; P = 0.023). The other molecules expressed in cancer cells did not exhibit any prognostic value. In NSCLC without neoadjuvant therapy (case control, n = 104), expression of ALDH1 in cancer cells was not correlated with prognosis (P = 0.507). A multivariate analysis identified ALDH1 expression in cancer cells as significantly independent prognostic factors for disease-free survival (P = 0.045). The current study indicated that the immunophenotypes of ALDH1 in cancer cells could have prognostic value for patients with NSCLC who are treated with neoadjuvant therapy.

AB - Prognostic factors for patients with non-small cell lung cancer (NSCLC) who have been treated with neoadjuvant therapy have not been fully assessed. The purpose of this study was to analyze prognostic biomarkers in NSCLC after treatment with neoadjuvant therapy, with special reference to the immunophenotypes of both the cancer cells and stromal cells. A total of 52 patients with NSCLC who were treated with neoadjuvant therapy followed by complete resection were included. We examined the expressions of nine markers in the cancer cells and stromal cells. The 5-year disease-free survival rate of patients with high aldehyde dehydrogenase 1 (ALDH1) expression levels in their cancer cells was significantly lower than those with a low ALDH1 level (47.3% vs. 21.5%, respectively; P = 0.023). The other molecules expressed in cancer cells did not exhibit any prognostic value. In NSCLC without neoadjuvant therapy (case control, n = 104), expression of ALDH1 in cancer cells was not correlated with prognosis (P = 0.507). A multivariate analysis identified ALDH1 expression in cancer cells as significantly independent prognostic factors for disease-free survival (P = 0.045). The current study indicated that the immunophenotypes of ALDH1 in cancer cells could have prognostic value for patients with NSCLC who are treated with neoadjuvant therapy.

KW - ALDH1

KW - Cancer stromal cell

KW - Cancer-initiating cell

KW - Neoadjuvant therapy

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84892467836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892467836&partnerID=8YFLogxK

U2 - 10.1111/pin.12122

DO - 10.1111/pin.12122

M3 - Article

C2 - 24422956

AN - SCOPUS:84892467836

VL - 63

SP - 599

EP - 606

JO - Pathology International

JF - Pathology International

SN - 1320-5463

IS - 12

ER -